Do Not Prescribe Clindamycin Vaginal Cream to Pregnant Women with Bacterial Vaginosis
Clindamycin 2% vaginal cream is contraindicated during pregnancy due to evidence of increased preterm delivery risk. 1 Instead, use oral systemic therapy with either metronidazole or oral clindamycin.
Recommended Treatment Approach
For High-Risk Pregnant Women (History of Preterm Delivery)
Screen and treat asymptomatic BV in the early second trimester:
- First-line: Metronidazole 250 mg orally three times daily for 7 days 1
- Alternatives:
- Metronidazole 2 g orally single dose, OR
- Clindamycin 300 mg orally twice daily for 7 days
For Low-Risk Pregnant Women (No Prior Preterm Delivery)
Treat only if symptomatic:
- First-line: Metronidazole 250 mg orally three times daily for 7 days 1
- Alternatives:
- Metronidazole 2 g orally single dose, OR
- Clindamycin 300 mg orally twice daily for 7 days, OR
- Metronidazole gel 0.75%, one full applicator (5 g) intravaginally twice daily for 5 days
Note: Some experts prefer systemic therapy over vaginal metronidazole gel to treat possible subclinical upper genital tract infections 1.
Critical Safety Concern
The 1998 CDC guidelines explicitly state that clindamycin vaginal cream use during pregnancy is not recommended because two randomized trials showed an increase in preterm deliveries among pregnant women treated with this medication. 1 This represents a direct harm to pregnancy outcomes—the opposite of the intended therapeutic goal.
The earlier 1993 CDC guidelines had recommended clindamycin vaginal cream for first-trimester use 2, but this recommendation was reversed after subsequent trial data emerged showing adverse outcomes 3, 4.
Why Systemic Therapy is Preferred
Lower medication doses are recommended during pregnancy to minimize fetal exposure, but systemic therapy is still preferred over vaginal clindamycin cream because:
- BV-associated organisms may harbor in the upper genital tract 1, 4
- Vaginal preparations may not adequately treat upper tract infection
- The mean bioavailability of clindamycin cream is only approximately 4% 1
- Research shows clindamycin vaginal cream can paradoxically worsen vaginal flora, changing normal flora to intermediate or BV patterns 3
Follow-Up Recommendations
For high-risk pregnant women, conduct a follow-up evaluation at 1 month after treatment completion to confirm therapeutic success, as treatment may prevent adverse pregnancy outcomes in this population 1.
Common Pitfall to Avoid
Do not extrapolate non-pregnant BV treatment guidelines to pregnancy. While clindamycin vaginal cream is an acceptable alternative for non-pregnant women with metronidazole allergy or intolerance 1, this does not apply during pregnancy due to the documented increased preterm delivery risk.